human liver carcinoma cell line hepg2 (ATCC)
Structured Review

Human Liver Carcinoma Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 29907 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+liver+carcinoma+hepg2+cells/Hep+G2/pmc13211382-62-8-14
Average 99 stars, based on 29907 article reviews
Images
1) Product Images from "Establishment and Validation of a Cell-Based Relative Potency Method for Respiratory Syncytial Virus mRNA Vaccine Drug Substance"
Article Title: Establishment and Validation of a Cell-Based Relative Potency Method for Respiratory Syncytial Virus mRNA Vaccine Drug Substance
Journal: Vaccines
doi: 10.3390/vaccines14050401
Figure Legend Snippet: Optimization of cell-related conditions for the RSV mRNA potency assay. ( A ) Dose–response curves of RSV mRNA transfection in different cell lines (293T, Vero, HEp-2, HepG2, and A549). Cells were transfected with increasing amounts of RSV mRNA (0.0002–0.48 µg/well), and RSV prefusion F protein expression was measured by ELISA as OD 450 –OD 630 . The corresponding EC 50 and slope values are summarized in the inset table. ( B ) Effect of HepG2 cell seeding density on RSV prefusion F protein expression. HepG2 cells were seeded at 0.5 × 10 5 , 1.0 × 10 5 , or 2.0 × 10 5 cells/well and transfected with increasing amounts of RSV mRNA (0.0002–0.48 µg/well). Protein expression was measured by ELISA as OD 450 –OD 630 .
Techniques Used: Potency Assay, Transfection, Expressing, Enzyme-linked Immunosorbent Assay
Related Articles
Cell Culture:Article Title: Blocked metabotropic glutamate receptor 5 enhances chemosensitivity in hepatocellular carcinoma and attenuates chemotoxicity in the normal liver by regulating DNA damage. Article Snippet: DNA damaging agents are used as chemotherapeutics in many cancers, including hepatocellular carcinoma (HCC).. However, they are associated with problems such as low sensitivity to chemotherapy and the induction of liver injury, underscoring the need to identify new therapies.. Here, we investigated the differential regulatory effect of metabotropic glutamate receptor 5 (mGlu5) on chemosensitivity in HCC and chemotoxicity to the normal liver. Article Title: Blocked Metabotropic Glutamate Receptor 5 Enhances Chemosensitivity in Hepatocellular Carcinoma and Attenuates Chemotoxicity in the Normal Liver by Regulating DNA Damage Article Snippet: Abbreviations: HCC, hepatocellular carcinoma; mGlu5, metabotropic glutamate receptor 5; PD, Parkinson's disease; MPEP, 2-methyl-6-(phenylethynyl) pyridine; MMS, methyl methanesulfonate; BAPTA, 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; CNS, central nervous system; MAPK, mitogen-activated protein kinase; CHPG, (RS)-2-Chloro-5hydroxyphenylglycine *Correspondence: Hong Zhang, Department of Neurobiology, School of Basic Medical Sciences, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China.. Telephone: +86 010 8395 0379.. E-mail address: hzhang@ccmu.edu.cn (H Zhang) 1 Blocked metabotropic glutamate receptor 5 enhances chemosensitivity in hepatocellular 2 carcinoma and attenuates chemotoxicity in the normal liver by regulating DNA damage 3 Hui-Min Yang a, Tian-Zhong Hou a, Ya-Nan Zhang a, Shu-Dong Zhao a, b, Yong-Le Wu c, 4 Hong Zhang a,* 5 a Department of Neurobiology, School of Basic Medical Sciences, Beijing Key Laboratory of 6 Neural Regeneration and Repair, Beijing Institute for Brain Disorders, Capital Medical 7 University, Beijing 100069, China 8 b Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing 9 Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, 10 Beihang University, Beijing, 100083, China 11 c Center of Hepatic and Digestive Disease, Beijing YouAn Hospital, Capital Medical 12 University, Beijing 100069, China This preprint research paper has not been peer reviewed. Article Title: Integrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models. Article Snippet: .. The L929 mouse skin fibroblasts (CCL-1, ATCC, USA) and THP1-BlueTM NF-κB reporter cells (InvivoGen, USA) were cultured in RPMI-1640 medium (Gibco, USA), human colorectal adenocarcinoma LoVo cells (CCL-229, ATCC, USA) were cultured in DMEM/F12 medium (Gibco, USA), and Article Title: Integrated safety and microbiota profiling of fulvic acid formulations across in vitro and in vivo models Article Snippet: .. The L929 mouse skin fibroblasts (CCL-1, ATCC, USA) and THP1-BlueTM NF-κB reporter cells (InvivoGen, USA) were cultured in RPMI-1640 medium (Gibco, USA), human colorectal adenocarcinoma LoVo cells (CCL-229, ATCC, USA) were cultured in DMEM/F12 medium (Gibco, USA), and Article Title: Selective Photoaffinity Probe for Monitoring Farnesoid X Receptor Expression in Cultured Cells. Article Snippet: Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, is a vital ligand-activated transcriptional factor, which is highly expressed in the liver, intestine, and adrenal gland.. However, FXR homeostasis is influenced by many factors, such as diet and circadian rhythm, and the expression of FXR differs in diverse organs.. Currently, there is no method to monitor the FXR homeostasis in real time, which restricts us from further investigating the function of FXR under physiological and pathological conditions. Article Title: Synthesis of Radioluminescent CaF 2 :Ln Core, Mesoporous Silica Shell Nanoparticles for Use in X-ray Based Theranostics Article Snippet: .. Murine fibroblast (NIH 3T3) and Modification:Article Title: Selective Photoaffinity Probe for Monitoring Farnesoid X Receptor Expression in Cultured Cells. Article Snippet: Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, is a vital ligand-activated transcriptional factor, which is highly expressed in the liver, intestine, and adrenal gland.. However, FXR homeostasis is influenced by many factors, such as diet and circadian rhythm, and the expression of FXR differs in diverse organs.. Currently, there is no method to monitor the FXR homeostasis in real time, which restricts us from further investigating the function of FXR under physiological and pathological conditions. Negative Control:Article Title: T-2 toxin and deoxynivalenol (DON) exert distinct effects on stress granule formation depending on altered activity of SIRT1. Article Snippet: .. Produced:Article Title: T-2 toxin and deoxynivalenol (DON) exert distinct effects on stress granule formation depending on altered activity of SIRT1. Article Snippet: .. Derivative Assay:Article Title: Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Article Snippet: Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy.. In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug−drug interactions (DDIs).. First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters. Stable Transfection:Article Title: Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Article Snippet: Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy.. In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug−drug interactions (DDIs).. First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters. Transduction:Article Title: Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Article Snippet: Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy.. In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug−drug interactions (DDIs).. First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters. |
![Genotoxic effect observed on LoVo (left) and <t>HepG2</t> (right) cell lines after 24 h incubation with tested preparations containing fulvic acid (MLG-50, MLG-A50) in the range of 1:8192–1:32768. Nucleus damage presented as tail DNA [%] (Lucia Comet Assay™, Laboratory Imaging). PBS was used as a non-treated control (NTC), and 50 µg/mL H 2 O 2 as a treated control. For each independent experiment, 50–100 nucleoids were randomly analyzed per condition. Data are shown as mean ± standard error of the mean (SEM) from four independent experiments ( n = 4). Statistics were performed using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons test; * indicates statistical significance versus the non-treated control (NTC) ( p < 0.05). Criteria for interpretation of damage levels were as follows: ≤5%—no or minor damage; 5–20%—low damage; 20–40%—moderate damage; 40–75%—high damage; >75%—severe damage.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_5387/pmc12905387/pmc12905387__41598_2026_37331_Fig2_HTML.jpg)

